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Background: The effects of highly active antiretroviral therapy (HAART) on glucose and lipid metabolism among
sub-Saharan Africans, for whom access to antiretroviral therapy is expanding, remain largely unknown. Therefore,
the aim of this study was to assess antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV
infected patients at Burayu health center, Addis Ababa, Ethiopia.
Methods: A cross-sectional comparative study was conducted among HIV infected adults at Burayu Health Center,
Addis Ababa, Ethiopia from September, 2011 to May, 2012. Equal number of HAART naïve and HAART initiated patients
(n = 126 each) were included in the study. Demographic data were collected using a well-structured questionnaire.
Total cholesterol (TC), Triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol
(LDL-C) and glucose were determined. The data were analyzed using SPSS version 20 software.
Result: Of 252 study participants, 72.2% were females; mean age was 35.3 years; mean Body Mass Index (BMI) was 21.4
(kg/m2); mean time living with the virus was 20.6 months and 15.5% were TB-HIV co-infected. The prevalence of
hyperglycemia, increased LDL-C hypercholesterolemia, hypertriglyceridemia and decreased HDL-C were 7.9%, 23%,
42.1%, 46.8% and 50.8% in HAART and 5.6%, 7.1%, 11.1%, 31% and 73% in non-HAART groups, respectively. First line
antiretrovirals were drugs containing 2 nucleoside backbones (from Zidovudine/Stavudine/Lamivudine/Tenofovir) with
either Nevirapine or Efavirenz. There was statistically significant increase in serum lipid profile levels among HAART
initiated patients than HAART naïve individuals (p =0.01 for TG and <0.001 for others).
Conclusion: First-line HAART is associated with potentially atherogenic lipid profile levels in patients with HIV infection
compared to untreated patients. This indicates glucose and lipid profile levels need to be monitored regularly in HIV
infected patients taking antiretroviral treatment.
Keywords: HIV/AIDS, Dyslipidemia, Hyperglycemia, Antiretroviral therapy, Ethiopia* Correspondence: mollish77@gmail.com
1Department of Clinical Chemistry, School of Biomedical and Laboratory
Sciences, College of Medicine and Health Sciences, University of Gondar,
Gondar, Ethiopia
Full list of author information is available at the end of the article
© 2014 Abebe et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Abebe et al. BMC Research Notes 2014, 7:380 Page 2 of 8
http://www.biomedcentral.com/1756-0500/7/380Background
Highly active antiretroviral therapy (HAART) is the main-
stay of treatment for those infected with HIV [1]. Since its
introduction in 1996, mortality and morbidity rates in HIV-
infected individuals in countries with widespread access to
HAART have plummeted. The main effect of HAART is to
suppress viral replication, allowing the individual’s immune
system to recover and protecting from the development of
AIDS and death [2]. In recent years, provision of HAART
to those in need has become an increasingly important and
feasible global priority [3]. However, the prospect of main-
taining patients on long term HAART may be restricted by
a heterogeneous collection of unexpected metabolic abnor-
malities, including dysregulation of glucose metabolism,
dyslipidemia, and/or lipodystrophy [4,5]. Use of HAART
has been linked to hyperglycemia, dyslipidemia and in-
creased risk of cardiovascular disease (CVD) in HIV-
infected patients in industrialized countries. The effects of
HAART on glucose and lipid metabolism among sub-
Saharan Africans, for whom access to antiretroviral therapy
is expanding, remain largely unknown [6]. This is specially
a major gap that should be given high emphasis in a county
like Ethiopia where increased use of HAART is higher since
2005. Therefore, the aim of this study was to assess anti-
retroviral treatment associated hyperglycemia and dyslipid-
emia among HIV infected patients at Burayu health center,
Addis Ababa, Ethiopia.
Methods
Study design, setting and period
A cross-sectional comparative study was conducted at vol-
untary counseling and testing (VCT) center of Burayu
Health Center in collaboration with Ethiopian Health and
Nutrition Research Institute (EHNRI) from September,
2011 to May, 2012. Two groups of study participants with
age ≥18 years who were either on HAART for at least six
months (HAART initiated group) and HAART naïve HIV
patients (non-HAART groups) who visited the VCT center
during the study period were included in the study.
First-line HAART regimens used were nucleoside reverse
transcriptase inhibitors (NRTIs) [lamivudine (3TC), zi-
dovudine (AZT), stavudine (D4T) or Tenofovir (TDF)] and
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
[nevirapine (NVP) or efavirenz (EFV)]. Patients with hyper-
glycemia or dyslipidemia at baseline (for HAART initiated
patients) and pregnant women and nursing mother were
excluded.
Data collection
Consecutive sampling technique was employed to include
study participants. Two hundred fifty two (126 HAART
initiated and 126 non-HAART) participants were enrolled.
After having received a clear explanation of the objective,
risk and confidentiality of the study, participants signedthe informed consent and participated in the study.
Demographic data regarding, age, gender, period with
HIV infection, ART exposure in the previous six months
and the ARV regimen were collected using questionnaire.
Medical records were also used to confirm the informa-
tion and baseline glucose and lipid profile levels. Height
and weight were measured to calculate body mass index
(BMI). Six to ten ml of blood sample was collected by
venipuncture from 8–12 hours fasting individuals using
vacuum tube (Becton Dickinson, SA) and serum was sepa-
rated within one hour of blood collection. The serum
levels of glucose, TC, HDL-C, LDL-C and TG were mea-
sured using COBAS INTEGRA 400 random access full
automated auto analyzer at EHNRI, clinical chemistry la-
boratory. Glucose was determined by Hexokinase (HK)
method, TG and total TC were evaluated with enzymatic
colorimetric method and HDL-C and LDL-C were ana-
lyzed by homogenous enzymatic colorimetric method.
CD4+ lymphocyte count was determined using flow
cytometer (FACSCalibur, Becton Dickinson, CA, USA).
Tuberculosis (TB) was diagnosed via microscopy from
sputum sample and X-ray photography if smear nega-
tive TB encountered.
The cutoff points to categorize dyslipidemia was defined
as TC ≥200 mg/dl, HDL-c <40 mg/dl, LDL-c ≥130 mg/dl,
TG ≥150 mg/dl and hyperglycemia as glucose ≥110 mg/dl
and were based on the United States National Cholesterol
Education Program, Adult Treatment Panel (NCEP-ATP)
III guideline [7].Data analysis
Data were entered and analyzed using Statistical Package
for Social Sciences (SPSS) window version 20 (IBM Statis-
tics, USA). Chi-square, student-t-test and logistic regres-
sion tests were used to see the association between socio-
demographic characteristics, duration with HIV, BMI and
HAART regimens with serum glucose and lipid profile
levels. P-Value <0.05 was considered to be statistically sig-
nificant at 95% confidence interval (CI).Ethical consideration
The study was ethically cleared from the Departmental
Research and Ethics Review Committee of Department of
Medical Laboratory Sciences, College of Health Sciences,
Addis Ababa University, Oromia Regional Health Bureau
Ethical Review Committee, EHNRI Scientific and Ethical
Review Committee and National Research Ethics commit-
tee of Ethiopia. VCT center counselors (nurses from the
Health Center) who collected patient data were oriented
and trained to keep data confidentiality. Patients received
their results through clinicians for further diagnosis and
treatment accordingly.
Table 1 Characteristics of study population by HAART
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N, number; BMI, body mass index; HAART, highly active antiretroviral therapy;
TB, tuberculosis; SD, standard deviation; *p-value =0.02; **p-value =0.004;
***p-value <0.0001.
Abebe et al. BMC Research Notes 2014, 7:380 Page 3 of 8
http://www.biomedcentral.com/1756-0500/7/380Results
Socio demographic characteristics of study subjects
A total of 252 HIV infected patients were enrolled in the
study. Of these, 126 (50%) were initiated HAART
(HAART group) and 126 (50%) were ART naive (non-
HAART group). Majority of the study participants were
females (182 (72.2%)). Of those HAART groups, 86
(68.3%) were females. In addition, among non-HAART
groups, 96 (76.2%) were females. The overall mean age
was 35.3 ± 10.2 years (range: 18 to 75 years). The total
time from the serological diagnosis of HIV infection was
20.6 ± 17.3 months (Mean ± SD) and was longer in
HAART group compared to non-HAART group (mean:
29.5 ± 17.1 versus 11.8 ± 12.3 months, p <0.0001). Thirty
four (27%) HAART groups and 25 (19.8%) non-HAART
groups had CD4+ cells <200 cells/mm3. Of all the sub-
jects, 39 (15.5%) had TB-HIV co infection during the
study period [21(16.7%) of the HAART and 18 (14.3%)
non-HAART groups] (Table 1).
Characteristics of serum fasting glucose and lipid
profile levels
Totally, 17 (6.7%) individuals had abnormally high fast-
ing serum glucose level. There was no significant differ-
ence in serum glucose level between HAART initiated
and non-HAART groups (P =0.45). However, there
was higher serum lipid profile levels among HAART
groups than HAART naïve individuals (p =0.01 for TG
and <0.001 for others) (Table 2).
Serum fasting glucose/lipid profile level and HAART
Most of the HAART initiated patients (43, 34.1%) were
on ART for 13–24 months followed by those for 25–41
months (42, 33.3%). The rest 28 (22.2%) and 13 (10.3%)
were on ART for 6–12 months and above 3.5 years, re-
spectively. Duration of HAART was not significantly as-
sociated with serum glucose/lipid profile levels.
A total of 4 nucleoside reverse transcriptase inhibitors
[Lamivudine (3TC), Zidovudine (AZT), Stavudine (D4T)
and Tenofovir (TDF)] and 2 non-nucleoside reverse
transcriptase inhibitors [Nevirapine (NVP) and Efavirenz
(EFV) with 5 combinations (D4T-3TC-NVP, AZT-3TC-
EFV, D4T-3TC-EFV, AZT-3TC-NVP and TDF-3TC-
EFV] were used to treat patients. Nevirapine and EFV
based combinations were used by almost equivalent
number of individuals [65(51.6%) versus 61(48.4%), re-
spectively]. In addition, D4T and AZT based ARVs were
used by 47 (37.3%) and 67 (53.2%) individuals, respect-
ively. AZT-3TC-NVP combinations of antiretrovirals
were the most frequently used drugs among the HAART
initiated study participants, [36 (28.6%)] while TDF-
3TC-EFV combinations were relatively used by small
number of patients, [12 (9.5%)] (Figure 1). No significant
difference observed in glucose/lipid profile derangementsbetween patients receiving AZT based combinations com-
pared to those on D4T; and patients treated with EFV
based combinations versus those treated with NVP
(Table 3).
Serum glucose/lipid profile levels and risk factors
Using univariate analysis, there was no statistically signifi-
cant association between serum glucose/lipid profile levels
and gender. However, there were statistically significant
association between TG and HAART initiation, TC and
HAART initiation, HDL-C and HAART initiation, and
LDL-C and HAART initiation (p = 0.01, <0.0001, < 0.0001
and 0.001, respectively). Glucose was not affected by dif-
ferent variables except by CD4+cells (p =0.023). Similarly,
tuberculosis (TB) co-infection slightly affected serum
LDL-C level only (p =0.49) (Table 4).
Table 2 Serum lipid profile and glucose levels of study
population by HAART status at Burayu Health Center,





N (%) N (%)
Glucose Mean ± SD 97.1 ± 15.7 92.2 ± 16.9*
≤110 mg/dl 116(92.1) 119(94.4)
>110 mg/dl 10(7.9) 7(5.6)
Triglycerides Mean ± SD 162.2 ± 92.7 131.5 ± 55.3**
<150 mg/dl 67(53.2) 87(69)
≥150 mg/dl 59(46.8) 39(31)*
Total
cholesterol
Mean ± SD 194.3 ± 45.2 147.2 ± 37.7***
<200 mg/dl 73(57.9) 112(88.9)
≥200 mg/dl 53(42.1) 14(11.1)***
HDL-
cholesterol
Mean ± SD 40.9 ± 12.9 32.6 ± 11.3***
<40 mg/dl 64(50.8) 92(73)***
≥40 mg/dl 62(49.2) 34(27)
LDL-
cholesterol
Mean ± SD 107.2 ± 35 81.4 ± 29.3***
<130 mg/dl 97(77) 117(92.9)
≥130 mg/dl 29(23) 9(7.1)***
HAART, highly active antiretroviral therapy; HDL, high-density lipoprotein; LDL,
low- density lipoprotein; SD, standard deviation; *p-value =0.01; **p-value =0.002;
*** p-value <0.0001.
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gender, age, BMI, CD4 + cells, duration with HIV, TB co-
infection and HAART initiation, HAART initiation and
BMI had an independent and positive association with
raised serum TC level. In addition, HAART initiationFigure 1 Frequency of different combinations of antiretroviral drugs
Ababa, Ethiopia, 2012.was independently associated with serum HDL-C and
LDL-C levels (Table 5).
Discussion
In this study, we tried to address how presence and ab-
sences of HAART affects glucose and lipid profile levels
in HIV positive individuals.
Our results showed an increased prevalence of hypergly-
cemia, hypercholesterolemia and hypertriglyceridemia in
patients receiving ARV drugs than non-HAART study
participants. The prevalence of hyperglycemia (>110 mg/
dl), low density lipoprotein cholesterol (LDL-C) hyper-
cholesterolemia (≥130 mg/dl), total cholesterol (TC)
hypercholesterolemia (≥200 mg/dl), hypertriglyceridemia
(≥150 mg/dl) and high density lipoprotein cholesterol
(HDL-C) hypocholesterolemia (<40 mg/dl) were 7.9%,
23%, 42.1%, 46.8% and 50.8% in HAART initiated and
5.6%, 7.1%, 11.1%, 31% and 73% in non-HAART groups,
respectively.
In this study, we found comparable percentage of
HAART initiated individuals (7.9%) and non- HAART
group (5.6%) who had an increased serum glucose level
and HAART initiation was not associated (p =0.45). How-
ever, HAART group showed higher mean glucose level
than non-HAART group (p =0.019). In agreement to this
finding, a study in Brazil observed elevated glucose levels
in 6.8% (7/103) patients treated without PIs, 1.5% (2/134)
patients receiving PIs and 0.9% (1/112) non-HAART indi-
viduals despite the small number cases limited their con-
clusions [8].
Among our study subjects, there was no association
between serum glucose/lipid level and gender. However,used by HIV infected patients at Burayu Health Center, Addis
Table 3 Serum glucose and lipid profile levels distribution
among different combinations of HAART taken by study
participants at Burayu Health Center, Addis Ababa,
Ethiopia, 2012
Glucose/lipid profile NVP versus EFV based
combination of ARVs
P-value
NVP (n=65) EFV (n=61)
N (%) N (%)
Glucose ≤110 60(92.3) 56(91.8) 0.917
>110 5(7.7) 5(8.2)
Triglyceride <150 37(56.9) 30(49.2) 0.384
≥150 28(43.1) 31(50.8)
Total cholesterol <200 37(56.9) 36(59) 0.812
≥200 28(43.1) 25(41)
HDL-cholesterol <40 28(43.1) 36(59) 0.074
≥40 37(56.9) 25(41)
LDL-cholesterol <130 48(73.8) 49(80.3) 0.388
≥130 17(26.2) 12(19.7)
Glucose/lipid profile D4T versus AZT based
combination of ARVs
P-value
D4T (n=47) AZT (n=67)
N (%) N (%)
Glucose ≤110 40(85.1) 64(95.5) 0.053
>110 7(14.9) 3(4.5)
Triglyceride <130 25(53.2) 35(52.2) 0.920
≥130 22(46.8) 32(47.8)
Total cholesterol <200 28(59.6) 39(58.2) 0.884
≥200 19(40.4) 28(41.8)
HDL-cholesterol <40 26(55.3) 33(49.3) 0.524
≥40 21(44.7) 34(50.7)
LDL-cholesterol <130 37(78.7) 53(79.1) 0.961
≥130 10(21.3) 14(20.9)
AZT, Zidovudine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; p, significance level.
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treated patients for an average of 39.35 months, the preva-
lence of hyperlipidemia was higher in men than women
despite no difference in blood glucose level between the
two. Among those reported patients, 6.5%, 10.5%, 34.0%
and 35.5% developed increased LDL-C, diabetes mellitus,
hypercholesterolemia and hypertriglyceridemia, respect-
ively [9]. The discrepancy with our study may be due to
our study participants were not gender matched between
the two groups.
Increased serum lipid profile level was associated with
HAART initiation (p = 0.01 for TG and <0.0001 for others)
in our study. Similar to our findings, a cross-sectional
study from India showed significantly higher prevalence of
dyslipidemia in the first line treatment groups [10]. More-
over, according to a study from the same country, atbaseline and at 12 months, TC was >200 mg/dl for 1% and
26% of patients; LDL-C level was >130 mg/ dl for 3% and
23%; HDL-C level was <40 mg/dl for 91% and 23% and
blood glucose level was >110 mg/dl for 14% and 13%, re-
spectively [11].
In Canada, among 745 ARV treated patients, 10% and
16% showed increased TG and TC levels, respectively [12].
Unlike to the above and in agreement with ours a study
from Cameroon showed the prevalence of TC ≥200 mg/dl
as 37.6% and 24.6%, respectively in ART groups and ART
naive groups (p =0.019). The equivalents for LDL-C ≥130
mg/dl were 46.4% and 21% (p ≤0.001) [13].
Inline to our finding, a long term analysis on plasma
lipid concentration was performed in patients starting
first-line antiretroviral therapy in Netherlands and showed
concentrations of TC, LDL-C and TG continued to in-
crease with slight decrease in HDL-C [14]. Similarly, a
study from Cameroon showed TC, LDL-C and HDL-C
levels increased significantly (P <0.05) but TG remained
unaltered with first line ARV therapy for 3 months [15].
This might be due to short treatment period.
In our HAART initiated study participants, the mean
serum HDL-C, LDL-C, TG and TC levels were 40.9, 107.2,
162.2 and 194.3 mg/dl, respectively. The result of another
1 year follow up study in Italy showed elevated mean levels
of serum HDL-C, 40.1 mg/dl; LDL-C, 165.2 mg/dl; TC,
258.7 mg/dl and TG, 306.4 mg/dl than ours. These mean
differences might be probably due to population difference
in Ethiopia and Italy. They found decreased HDL-C level
9.4%, hypercholesterolemia 25%, increased LDL-C level
26.7% and hypertriglyceridemia 38.2% [16] which was al-
most comparable with our results. Moreover, a 5 year co-
hort study in Switzerland found that non-HDL-C levels
increased with increasing exposure to either PIs or NNRTI
based therapy, HDL-C level increased and TG level de-
creased with increasing exposure to NNRTI based therapy;
whereas TG levels increased with increasing exposure to
PI-based therapy [17].
In logistic regression adjusted for age group, duration
with HAART, BMI, CD4+ cell count, and TB-HIV co-
infection, HAART initiation was significantly associated
with serum TC, HDL-C and LDL-C levels. Similarly, a
study conducted in Cameroon in 2011, in multivariable
analysis adjusted for age, sex, BMI, CD4+ cell count and
co-infection with tuberculosis, being on ART was signifi-
cantly and positively associated with raised TC and
LDL-C with adjusted odd ratios (95% CI, p-value) ART-
treated versus ART-naïve was 1.82 (1.06_1.12, p =0.02)
for TC ≥200 mg/dl and 2.99 (1.74_5.15), p <0.0001) for
LDL-C ≥130 mg/dl [13].
With a combination of at least three drugs including
NRTI, NNRTI and PIs, HAART is currently used to
control the replication of HIV and AIDS [8]. Even
though, the national ART guideline for adolescents and
Table 4 Association of glucose and lipid profile levels and other variables at Burayu Health Center, Addis Ababa,
Ethiopia, 2012
Variables Glucose/lipid profile levels
Gluc >110 mg/dl TG≥ 150 mg/dl TC≥ 200 mg/dl HDL < 40 mg/dl LDL≥ 130 mg/dl
UOR (95% CI) UOR (95% CI) UOR (95% CI) UOR (95% CI) UOR (95% CI)
Gender (Female) 0.52(0.19-1.43) 0.62(0.36-1.10) 1.18(0.63-2.23) 1.37(0.77-2.45) 1.85(0.77-4.42)
P-value 0.208 0.097 0.608 0.289 0.167
Age ≥35years 1.52(0.56-4.12) 1.23(0.78-2.14) 2.30(1.29-4.10) 1.38(0.83-2.30) 2.57(1.23-5.35)
P-value 0.414 0.329 0.005 0.217 0.012
BMI >21.2 0.94(0.35-2.53) 1.27(0.76-2.11) 2.21(1.24-3.92) 1.78(1.07-2.98) 1.78(0.88-3.60)
P-value 0.908 0.358 0.007 0.028 0.108
CD4 + cells <200/mm3 3.21(1.18-8.73) 1.59(0.88-2.86) 0.82(0.42-1.62) 0.96(0.52-1.75) 0.57(0.23-1.44)
P-value 0.023 0.124 0.570 0.884 0.233
HAART Initiated 1.47(0.54-3.98) 1.96(1.17-3.29) 5.81(3.01-11.2) 2.62(1.55-4.44) 3.89(1.76-8.61)
P-value 0.453 0.01 <0.0001 < 0.0001 0.001
HIV duration ≥20 months 1.12(0.42-2.99) 1.19(0.72-1.98) 1.98(1.11-3.51) 1.37(0.82-2.28) 2.11(1.03-4.35)
P-value 0.828 0.500 0.020 0.231 0.042
TB infection 1.19(0.32-4.33) 1.11(0.56-2.23) 0.80(0.36-1.79) 0.68(0.33-1.42) 2.28(1.00-5.18)
P-value 0.798 0.590 0.590 0.307 0.049
HAART, highly active antiretroviral therapy; Gluc, glucose; UOR, un adjusted odds ratio; CI, confidence interval; BMI, body mass index; TC, total cholesterol; HDL,
high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride; p, significance level; TB, tuberculosis.
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[18], only first line regimens, NRTI and NNRTI, were
taken by the study participants at Burayu Health Center.
Two nucleoside backbones (from AZT/D4T/3TC/TDF)
with either NVP or EFV NNRTIs combinations were
used. AZT-3TC-NVP combination was the most fre-
quently used drug in study participants, 36 (28.6%).
In addition to its benefit antiretroviral drugs have been
associated with an abnormal fat redistribution syndrome
that might raise cholesterol and triglycerides levels, as well
as cause insulin resistance [4,5]. In line with this, our study
showed significant increase of serum lipid levels inTable 5 Association between cholesterol and HAART
initiation, adjusted for the potential confounding factors
of study participants at Burayu Health Center, Addis
Ababa, Ethiopia, 2012
Variables Lipid profile levels
TC ≥200 mg/dl HDL < 40 mg/dl LDL ≥130 mg/dl
AOR (95% CI) AOR (95% CI) AOR (95% CI)
Non-HAART* 1.00 1.00 1.00
HAART Initiated 5.46(2.81-10.61) 2.62(1.55-4.44) 3.89(1.76-8.61)
P-value <0.0001 <0.0001 0.001
BMI ≤21.2* 1.00 1.00 1.00
BMI >21.2 1.90(1.03-3.50)
P-value 0.039
HAART, highly active antiretroviral therapy; AOR, adjusted odds ratio; CI, confidence
interval; BMI, body mass index; TC, total cholesterol; HDL, high-density lipoprotein
cholesterol; LDL, low-density lipoprotein cholesterol;
p, significance level; *Reference category.HAART group than non-HAART group. There was no sig-
nificant difference of serum lipid profile and glucose levels
among different nucleoside combinations of HAART. In
contrast, a study from India [10] and Canada [12] showed
a significant association of lipoatrophy with D4T use. Espe-
cially in Canada, an incident lipoatrophy was associated
with duration of D4T [12]. Unlike to these, studies form
Spain and France showed the absence of difference in lipid
profiles between D4T and AZT treated patients [19,20].
Compared to each other, the independent effect of the
use of NVP and EFV based combinations on serum lipid
profile level was not seen among our study participants.
On the contrary, a 48 week follow up study in Australia
found that, the increase of HDL-C was significantly larger
for patients receiving NVP than for patients receiving
EFV, while the increase in TC was lower. The increase of
non-HDL-C was smaller for patients receiving NVP than
for patients receiving EFV, as were the increases of TG
and LDL-C [21]. In addition, a study in India found that
TC level >200 mg/dl was more common among patients
who received EFV than among those who received NVP
[11]. Moreover, a study in USA and Europe found that
EFV was associated with higher levels of TC and TG than
was NVP [22].
Limitations of the study
This is a cross-sectional study with no follow up of patients
to see the effects of HAART at individual level. In addition,
this paper does not include all potential confounders of
hyperglycemia and dyslipidemia such as physical exercise.
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First-line HAART with regimens NRTIs and NNRTIs were
associated with potentially atherogenic lipid profile levels
compared to untreated HIV infected patients in Ethiopian
setting. There were an increased prevalence of hypergly-
cemia, hypertriglyceridemia and hypercholesterolemia in
HAART initiated patients than non-antiretroviral HIV in-
fected patients at Burayu Health Center. This might lead
to metabolic complications particularly diabetes mellitus
and dyslipidemia which potentially increase risk of cardio-
vascular diseases. From these findings, serum fasting glu-
cose and lipid profile levels needs to be monitored
regularly in HIV infected patients on or without antiretro-
viral therapy to rule out unwanted effects that can be opti-
mally managed. In addition, further studies on well-
controlled cohort conditions for the evaluation of long-
term effects of HAART treatment on serum glucose and
lipid profile level are recommended.
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